The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer.

FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.